Condition

HIV Neuropathy

ClinicalTrials.gov condition label

Clinical trials5

Recruiting0

Common interventions12

Lead sponsors shown5

Clinical trials

5 shown

Symptom Management Efficacy Study to Reduce Distal Neuropathic PainNCT03855111 · 2019-01-14

OPEN Feasibility StudyNCT03584412 · 2018-07-09

Effect of Cannabis and Endocannabinoids on HIV Neuropathic PainNCT03099005 · 2018-07-01

A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral NeuropathyNCT01537705 · 2012-03-01

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain ConditionsNCT00904202 · 2003-01-01

Common interventions

ACT OPENBEHAVIORAL1 CannabisDRUG1 Gabapentin + Lidoderm®DRUG1 Gabapentin + PlaceboDRUG1 Gabapentin 1800 mg/day + Lidoderm patchDRUG1 Gabapentin 300 mg capsules 1800 mg/day + placebo patchDRUG1 Individualized (Tailored) Active Acupuncture / MoxibustionOTHER1 Neuron012703 (Medical Food)DRUG1 Placebo capsules + Lidoderm®DRUG1 Placebo Capsules + Placebo PatchDRUG1 Standard Acupuncture / MoxibustionOTHER1 Waiting list controlOTHER1

Leading sponsors

Endo USA Inc., a Keenova Therapeutics Company1 King's College London1 New York University1 Targeted Medical Pharma1 University of California, San Diego1

Trial status mix

COMPLETED3

UNKNOWN2

Phase mix

NA2

PHASE22

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.